

ANIMAL HEALTH ADVISORY COMMITTEE Working Group of the Advisory Group on the Food Chain

Future rules for the use of VMPs for disease prevention and control

Brussels, 07 June 2022

# **Draft Delegated act**

on the use of veterinary medicinal products for disease prevention and control



# AHL: Rules for the use of VMPs for disease prevention and control

### Article 46(1)

Provides for the possibility for the Member States to take measures concerning **the use of (ALL) veterinary medicinal products** to ensure the most efficient **prevention or control** of (ALL) listed diseases. These measures may cover prohibitions, restrictions and compulsory use of veterinary medicinal products and must be previously assessed as proportionate and necessary.


### Article 47(1) (empowerment)

Empowers the Commission to adopt delegated acts concerning:

- prohibitions and restrictions on the use of veterinary medicinal products;
- specific conditions for the use of veterinary medicinal products for a specific listed disease;
- risk-mitigation measures to prevent the spread of listed diseases through animals treated with the veterinary medicinal products or products from such animals;
- surveillance for specific listed diseases following the use of vaccines and other veterinary medicinal products.



# Future rules for the use of VMPs for disease prevention and control




#### **Category C and D diseases**

Article 46 of AHL, CDR (EU) 2020/688 (for movements within the Union) and CDR (EU) 2020/689 (for eradication programmes and freedom status) apply



## Proposed approach

# Rules on the use of **certain VMPs** for prevention and control of **certain listed diseases - Terrestrial and Aquatic animals**



This (draft) Act does not interfere with the scope of Regulation (EU) 2019/6



# Restrictions on the use of certain VMP's Category A and B diseases



**Antibiotics** 

Diagnostic immunological veterinary medicinal products


Exceptions: tuberculine and bruceline

> Inactivated immunological VMP, as referred to in Article 2(3) of Regulation (EU) 2019/6 [so-called 'auto-vaccines']

### Hyper-immune serum

#### Antivirals













### Preventive vaccination

✓ General rules



Disease-specific conditions available only for HPAI [for the moment]


## Vaccination against Newcastle Disease

Special status for "routine precautionary vaccination"





### **Decision Making - Implementation process** for the use of vaccines in animals for Category A diseases





# State of play

- Rules discussed in 8 Expert Group meetings (incl. a questionnaire to MS experts) (Doc SANTE 7144/2020) from March 2020 until May 2022
- Finalisation of internal consultation and final modifications: June 2022
- Public feedback: June July 2022
- Translation: July-August 2022
- Adoption by the COMM: August-September 2022
- EP and Council objection period: September-October 2022
- OJ Publication: November-December 2022



# Thank you



© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the <u>CC BY 4.0</u> license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.



Slide xx: element concerned, source: e.g. Fotolia.com; Slide xx: element concerned, source: e.g. iStock.com